Literature DB >> 22878561

Herbal, vitamin, and mineral supplement use in patients enrolled in a cardiac rehabilitation program.

Reynaria Nieva1, Seyed A Safavynia, Kathy Lee Bishop, Sperling Laurence.   

Abstract

PURPOSE: The use of complementary and alternative medicine is common and continues to rise each year, both in the general population and among those with cardiovascular disease. While some supplements may incur risk, particularly when used concomitantly with cardiovascular medications, others have proven benefits. However, supplements such as antioxidants and many herbs can have significant interactions with cardiovascular medications. This study aimed to identify the percentage of patients enrolled in a cardiac rehabilitation program taking herbal, vitamin, and mineral supplements.
METHODS: Electronic and paper charts of 235 patients enrolled in a phase 3 cardiac rehabilitation program were reviewed. Their demographics, medical history, and medications were stratified in an Excel chart, using a large matrix from which data were imported into Matlab for analysis. Custom Matlab programs were created and compiled to determine variables of interest, including percentages of patients with a specific medical condition taking certain supplements.
RESULTS: Sixty-seven percent of patients enrolled in the cardiac rehabilitation program were taking vitamins, with or without minerals (67%, 158 of 235). Multivitamin is the most common form of supplement (51%, 119 of 235), followed by fish oil/omega-3 polyunsaturated fatty acids (27%, 64 of 235).
CONCLUSION: The majority of patients in a phase 3 cardiac rehabilitation program are taking some form of herbal, vitamin, or mineral supplement. Given frequent, complicated patient medication regimens, it is important to educate patients on the potential benefits as well as lack of evidence and possible dangers of supplements.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22878561      PMCID: PMC4317371          DOI: 10.1097/HCR.0b013e31825f78f0

Source DB:  PubMed          Journal:  J Cardiopulm Rehabil Prev        ISSN: 1932-7501            Impact factor:   2.081


  49 in total

1.  Plasma homocysteine concentrations and risk of coronary heart disease in UK Indian Asian and European men.

Authors:  J C Chambers; O A Obeid; H Refsum; P Ueland; D Hackett; J Hooper; R M Turner; S G Thompson; J S Kooner
Journal:  Lancet       Date:  2000-02-12       Impact factor: 79.321

2.  n-3 fatty acids and cardiovascular events after myocardial infarction.

Authors:  Daan Kromhout; Erik J Giltay; Johanna M Geleijnse
Journal:  N Engl J Med       Date:  2010-08-28       Impact factor: 91.245

3.  Costs of complementary and alternative medicine (CAM) and frequency of visits to CAM practitioners: United States, 2007.

Authors:  Richard L Nahin; Patricia M Barnes; Barbara J Stussman; Barbara Bloom
Journal:  Natl Health Stat Report       Date:  2009-07-30

4.  Effects of homocysteine-lowering with folic acid plus vitamin B12 vs placebo on mortality and major morbidity in myocardial infarction survivors: a randomized trial.

Authors:  Jane M Armitage; Louise Bowman; Robert J Clarke; Karl Wallendszus; Richard Bulbulia; Kazem Rahimi; Richard Haynes; Sarah Parish; Peter Sleight; Richard Peto; Rory Collins
Journal:  JAMA       Date:  2010-06-23       Impact factor: 56.272

5.  Antioxidant supplements block the response of HDL to simvastatin-niacin therapy in patients with coronary artery disease and low HDL.

Authors:  M C Cheung; X Q Zhao; A Chait; J J Albers; B G Brown
Journal:  Arterioscler Thromb Vasc Biol       Date:  2001-08       Impact factor: 8.311

6.  Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy.

Authors:  William E Boden; Jeffrey L Probstfield; Todd Anderson; Bernard R Chaitman; Patrice Desvignes-Nickens; Kent Koprowicz; Ruth McBride; Koon Teo; William Weintraub
Journal:  N Engl J Med       Date:  2011-11-15       Impact factor: 91.245

Review 7.  Effects of lowering homocysteine levels with B vitamins on cardiovascular disease, cancer, and cause-specific mortality: Meta-analysis of 8 randomized trials involving 37 485 individuals.

Authors:  Robert Clarke; Jim Halsey; Sarah Lewington; Eva Lonn; Jane Armitage; JoAnn E Manson; Kaare H Bønaa; J David Spence; Ottar Nygård; Rex Jamison; J Michael Gaziano; Peter Guarino; Derrick Bennett; Fraz Mir; Richard Peto; Rory Collins
Journal:  Arch Intern Med       Date:  2010-10-11

8.  OMEGA, a randomized, placebo-controlled trial to test the effect of highly purified omega-3 fatty acids on top of modern guideline-adjusted therapy after myocardial infarction.

Authors:  Bernhard Rauch; Rudolf Schiele; Steffen Schneider; Frank Diller; Norbert Victor; Helmut Gohlke; Martin Gottwik; Gerhard Steinbeck; Ulrike Del Castillo; Rudolf Sack; Heinrich Worth; Hugo Katus; Wilhelm Spitzer; Georg Sabin; Jochen Senges
Journal:  Circulation       Date:  2010-11-08       Impact factor: 29.690

9.  Effects of oral niacin on endothelial dysfunction in patients with coronary artery disease: results of the randomized, double-blind, placebo-controlled INEF study.

Authors:  Ascan Warnholtz; Philipp Wild; Mir Abolfazl Ostad; Veronika Elsner; Fabian Stieber; Reinhard Schinzel; Ulrich Walter; Dirk Peetz; Karl Lackner; Stefan Blankenberg; Thomas Munzel
Journal:  Atherosclerosis       Date:  2008-08-12       Impact factor: 5.162

10.  Effects of B vitamins and omega 3 fatty acids on cardiovascular diseases: a randomised placebo controlled trial.

Authors:  Pilar Galan; Emmanuelle Kesse-Guyot; Sébastien Czernichow; Serge Briancon; Jacques Blacher; Serge Hercberg
Journal:  BMJ       Date:  2010-11-29
View more
  2 in total

1.  Medication and Dietary Supplement Interactions among a Low-Income, Hospitalized Patient Population Who Take Cardiac Medications.

Authors:  Paula Gardiner; Amanda C Filippelli; Ekaterina Sadikova; Laura F White; Brian W Jack
Journal:  Evid Based Complement Alternat Med       Date:  2015-04-12       Impact factor: 2.629

2.  Cannabidiol Inhibits Tau Aggregation In Vitro.

Authors:  Soha Alali; Gholamhossein Riazi; Mohammad Reza Ashrafi-Kooshk; Sogol Meknatkhah; Shahin Ahmadian; Mohammad Hooshyari Ardakani; Baharak Hosseinkhani
Journal:  Cells       Date:  2021-12-13       Impact factor: 6.600

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.